Belite Bio price target raised to $79 from $57 at Benchmark

Benchmark raised the firm’s price target on Belite Bio (BLTE) to $79 from $57 and keeps a Buy rating on the shares. After speaking to management at a conference last week, the firm revisited its pricing assumptions for Tinlarebant in the treatment of Stargardt disease type 1 and now assumes an average price of $50,000, the analyst tells investors.